91-day Levonorgestrel Oral Contraceptive

DRUG3 trials

Sponsors

Duramed Research, Teva Women's Health

Conditions

Bone Mineral DensityHemostasisMigraineOral Contraceptive

Phase 2

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

CompletedNCT00781456

Duramed ResearchMigraine

Start: 2009-01-31End: 2011-08-31Updated: 2017-02-06

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

CompletedNCT00924560

Duramed ResearchBone Mineral Density

Start: 2009-06-30End: 2012-08-31Updated: 2014-10-22

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

CompletedNCT01252186

Teva Women's HealthHemostasis, Oral Contraceptive

Start: 2010-11-30End: 2011-12-31Updated: 2015-03-13